These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7795143)

  • 61. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
    Fischer K; van der Bom JG; Molho P; Negrier C; Mauser-Bunschoten EP; Roosendaal G; De Kleijn P; Grobbee DE; van den Berg HM
    Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
    Brakman GG
    Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
    Khawaji M; Astermark J; Berntorp E
    Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.
    Weatherall J; Barnes N; Brown C; Préaud E
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):411-4. PubMed ID: 21831021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management of haemophilia in Sweden.
    Nilsson IM
    Thromb Haemost; 1976 Jun; 35(3):510-21. PubMed ID: 989956
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adherence to prophylactic treatment in patients with haemophilia in Germany.
    Miesbach W; Kalnins W
    Haemophilia; 2016 Sep; 22(5):e367-74. PubMed ID: 27353213
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hemophilia.
    Kashyap R; Choudhry VP
    Indian Pediatr; 2000 Jan; 37(1):45-53. PubMed ID: 10745388
    [No Abstract]   [Full Text] [Related]  

  • 71. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
    Aledort LM; Cohen M; Hilgartner M; Lipton R
    Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
    [No Abstract]   [Full Text] [Related]  

  • 72. Issues in pediatric haemophilia care.
    Giordano P; Franchini M; Lassandro G; Faienza MF; Valente R; Molinari AC
    Ital J Pediatr; 2013 Apr; 39():24. PubMed ID: 23601343
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 74. How do we optimally utilize factor concentrates in persons with hemophilia?
    Lim MY
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):206-214. PubMed ID: 34889393
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The impact of prophyactic treatment on children with severe haemophilia.
    Liesner RJ; Khair K; Hann IM
    Br J Haematol; 1996 Mar; 92(4):973-8. PubMed ID: 8616096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [New viewpoints in the treatment of hemophilia].
    Göbel U
    Dtsch Med Wochenschr; 1973 Sep; 98(39):1814-6. PubMed ID: 4583442
    [No Abstract]   [Full Text] [Related]  

  • 78. On-demand treatment in persons with severe haemophilia.
    Saulyte Trakymiene S; Steen Carlsson K
    Eur J Haematol Suppl; 2014 Aug; 76():39-47. PubMed ID: 24957106
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prophylactic treatment in Sweden--overtreatment or optimal model?
    Ljung RC
    Haemophilia; 1998 Jul; 4(4):409-12. PubMed ID: 9873762
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Experience of prophylaxis treatment in children with severe haemophilia.
    Yee TT; Beeton K; Griffioen A; Harrington C; Miners A; Lee CA; Brown SA
    Haemophilia; 2002 Mar; 8(2):76-82. PubMed ID: 11952841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.